1
1
6
↑1
↓1
—6
Evidence suggests MDMA haslittle to no effecton Adverse events.
7 studies (8 claims)
Emerging evidence
Typical effective dose 125 (82.5–125) mgacross 3 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| MDMA-assisted psychotherapy (MDMA-AT) | No effect - no significant difference regarding the incidence | ≥1 treatment-emergent adverse events (TEAE) | Human | participants with PTSD | Inactive doses of MDMA (25-40 mg) in the control group; active doses not specified in the abstract. | MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).cited 4× |
| MDMA-assisted psychotherapy | No effect - No drug-related serious adverse events occurred | serious adverse events | Human | patients with treatment-resistant PTSD | Low-dose (25 mg plus 12.5 mg supplemental) or full-dose (125 mg plus 62.5 mg supplemental) MDMA administered during three experimental sessions. | A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).cited 226× |
| MDMA-assisted psychotherapy | No effect - no drug-related serious adverse events | serious adverse events | Human | people with chronic posttraumatic stress disorder | 40 mg, 100 mg, and 125 mg administered during eight-hour psychotherapy sessions (two sessions for active doses, with additional open-label sessions). | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.cited 123× |
| MDMA | No effect - was not marked as the primary suspect | cardiovascular adverse events | Human | 17 cases of cardiovascular AEs | Not mentioned | Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system.cited 3× |
| MDMA | No effect - There were no drug-related serious adverse events | serious adverse events | Human | patients with chronic posttraumatic stress disorder, refractory to both psychotherapy and psychopharmacology | Not specified in the abstract. | The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.cited 373× |
| MDMA | Decreases - have been rare and non-life threatening | Serious Adverse Events (SAEs) | Human | individuals in clinical trials | Not specified. | MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.cited 58× |
| MDMA | No effect - without the occurrence of unexpected drug-related SAEs | Serious Adverse Events (SAEs) | Human | over 1133 individuals for research purposes | Not specified. | MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.cited 58× |